Ten innovations spanning diagnostics, AI, mobili

A Tokyo startup called TIME TRAVELER thinks the

Zsolt Farkas of Evolut on why today’s longevit

The AI drug developer nominated ISM1354 for obes

VectorY Therapeutics expanded its Phase 1/2 PIONE

Better U and Evernow announced a strategic telehe

Kailera Therapeutics announced completion of enro

Longeveron will take part in three longevity and

Arvinas will present novel biomarker data from a

Amprion and Prema Cognition announced a collabora

MitoRx Therapeutics presented preclinical transmi

Monte Rosa Therapeutics reported positive Phase 1

At ARDD 2026, senior FDA officials sketch how a

The maker of sasineprocel, a patient-derived cel

A retrospective study of 345 paired tests found

Basecamp Research will train AI models on the wo

13th Aging Research and Drug Discovery meeting o

Eccogene has received a $50 million milestone pay

Diagnostic Imaging Centers of Texas has expanded

Tiny Health announced a $33 million Series B led

Prenuvo launched the Prenuvo Research Network to

Insilico Medicine has nominated ISM1354, an AI-dr

Longevica Therapeutics has assembled a multidisci

Amorepacific and Junevity have entered into a col

Younger founder Christin Glorioso on turning a s

Postgraduate program aims to turn geroscience, b

Allergan Aesthetics is pairing new hallmarks-of-

Regenerative platforms reach patients on a diffe

Immortal Dragons has made a strategic investment

Deep Longevity will launch Accrua, a consumer dig

Cognition Therapeutics has scheduled a Type C mee

Dr Sean Leng and the Johns Hopkins-SunInflam tea

LW-1017, an oral drug that switches the brain’

One-year results for the open-chest version look

Amorepacific deal puts therapeutic target discov

AbbVie announced that the FDA has approved Juvmo

Arvinas announced that the first participant has

4DMT has enrolled first patients in its 4SIGHT gl

A further $173 billion a year is real on paper – but only once three separate regulatory clocks finish running down. With thanks to MuseCell Innovations, sponsor of the Longevity Biotech Report. The $230 billion pipeline needs nothing from anyone. It exists inside disease categories regulators already recognize, using approval routes already walked a thousand times over. The $173 billion sitting on top of it is a rather different proposition. It requires a category that does not yet exist – a recognized gerotherapeutic endpoint – to come into being first, and everything about its size depends on when, or whether, that happens. Longevity.Technology: This is, by some distance, the most conditional number in our Longevity Biotech Report. An additional $173b a year at its peak, reached in 2052, layered on top of the $230b rather than double-counted against it – bring the two together and the combined figure comes to $403b. Our report calls the underlying 2035 assumption conservative. That is precisely the kind of claim worth testing rather than simply accepting, because a number this large resting on a single regulatory pivot deserves rather more scrutiny than a confident adjective. Three clocks, one deadline Ask why 2035, and not…

The 4th Roundtable of Longevity Clinics meets at

Resolution Therapeutics has treated its last EME

Slow-release apomorphine patch just passed first

Regenxbio presented three-year durability data fo

Immorta Bio Inc.

Variant Bio has expanded its multi-year research

As longevity moves toward increasingly personali

Pathways Bioscience announced that a randomized,

Coya Therapeutics hits its 100th ALS trial enrol

Inside the $230 billion our new Longevity Biotec

Telomir’s oncology compound helped fish with a